2329669-72-7
2329669-72-7
Chemical Structure
Vudalimab
Synonym(s): XmAb20717
- CAS No.: 2329669-72-7
- Molecular Weight:(144.5 kDa)
SMILES: [Vudalimab]
Biological Activity: Vudalimab (XmAb20717) is a bispecific antibody that binds PD-1 and CTLA-4. Vudalimab preferentially binds to cells co-expressing PD-1 and CTLA-4 and blocks inhibitory checkpoint signaling to promote T cell activation. Vudalimab can be used for research in metastatic castration-resistant prostate cancer (including high-risk disease) and gynecological malignancies[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vudalimab | ≥99.0% | Vudalimab (XmAb20717) is a bispecific antibody that binds PD-1 and CTLA-4. Vudalimab preferentially binds to cells co-expressing PD-1 and CTLA-4 and blocks inhibitory checkpoint signaling to promote T cell activation. Vudalimab can be used for research in metastatic castration-resistant prostate cancer (including high-risk disease) and gynecological malignancies. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Stein MN, et al. A phase 2, multicenter, parallel-group, open-label study of vudalimab (XmAb20717), a PD-1 x CTLA-4 bispecific antibody, alone or in combination with chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer. J Clin Oncol. 2022;40(16 suppl):TPS5097.
- [2]. Hou J, et al. A phase 2 study of vudalimab (XmAb®20717), an anti-PD-1/CTLA-4 bispecific antibody, in patients with selected gynecological malignancies and high-risk metastatic castration-resistant prostate-cancer. J Immunother Cancer. 2022;10(Suppl 2):A765. Abstract 733.
- [3]. Hedvat M, et al. Abstract 2784: Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation. Cancer Res. 2018;78(13 suppl):2784.
